Toggle Main Menu Toggle Search

Open Access padlockePrints

Insulin detemir: From concept to clinical experience

Lookup NU author(s): Emeritus Professor Philip Home


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Insulin detemir (LevemirĀ®, Novo Nordisk) is a novel, biologically engineered analogue of human insulin that has been successfully developed for clinical use in diabetes as a basal insulin. Its unique mechanism of prolongation of action, achieved through acylation to give reversible albumin binding and additional self-association, goes some way to addressing one of the fundamental limitations of previously available, subcutaneously administered basal insulins, a high level of within-person variability in time-action profile from one injection to another. The pharmacological profile of insulin detemir, characterised in a series of studies, suggested it had the potential to offer efficacy and tolerability advantages in the clinical setting. Such advantages, in comparison to NPH (neutral protamine Hagedorn) insulin, have subsequently been illustrated in trials. Despite glucose control targets that are identical to comparators, insulin detemir achieved levels of glycaemic control that, overall, were at least as good as NPH insulin in the Phase III development programme, with lower variability being a consistent finding. This was associated with consistent risk reductions in nocturnal hypoglycaemic events, which are closely linked with the basal component of insulin therapy. Another consistent finding has been a significantly reduced propensity for weight gain. An all-analogue regimen combining insulin detemir with the rapid-acting insulin aspart illustrated the potential benefits achievable when insulins that are designed to achieve defined pharmacokinetic profiles are employed clinically; blood glucose control, including hypoglycaemia, was significantly superior to a human insulin-based mealtime plus basal regimen. Insulin detemir is, therefore, a valuable addition to the range of exogenous insulins, as it should enable treatment regimens to be constructed that offer good outcomes of efficacy and tolerability. Ā© 2006 Ashley Publications.

Publication metadata

Author(s): Home P, Kurtzhals P

Publication type: Review

Publication status: Published

Journal: Expert Opinion on Pharmacotherapy

Year: 2006

Volume: 7

Issue: 3

Pages: 325-343

ISSN (print): 1465-6566

ISSN (electronic): 1744-7666


DOI: 10.1517/14656566.7.3.325

PubMed id: 16448327